AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RACE ONCOLOGY LTD

2.450

+0.1606.99%

Volume:108.69K

Turnover:256.20K

Market Cap:442.93M

PE:-88.13

High:2.450

Open:2.300

Low:2.260

Close:2.290

52wk High:4.900

52wk Low:0.920

Shares:180.79M

Float Shares:121.21M

Volume Ratio:0.85

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.028

EPS(LYR):-0.028

ROE:-27.89%

ROA:-15.63%

PB:27.66

PE(LYR):-88.24

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies+1.74%

Capital Flow

Inflow:

Outflow:

News

Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance

MT Newswires Live

Racura Oncology Says Potential of Proprietary Formulation to be Evaluated Early This Year; Shares Fall 7%

MT Newswires Live

Atomic Eagle And 2 More ASX Penny Stocks To Watch

Simply Wall St.

Racura Partners With US-University to Study Lead Asset in Osimertinib-Resistant Non-Small Cell Lung Cancer

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":2.45,"timestamp":1770700320000,"preClose":2.29,"halted":0,"volume":108691,"delay":0,"changeRate":0.06986899563318784,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":180786237,"eps":-0.0278,"marketStatus":"Closed","change":0.16,"latestTime":"02-10 16:12:00 AEDT","open":2.3,"high":2.45,"low":2.26,"amount":256197,"amplitude":0.082969,"askPrice":2.45,"askSize":12351,"bidPrice":2.3,"bidSize":2641,"shortable":3,"etf":0,"ttmEps":-0.0278,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.29,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.852367,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-15.63%","roe":"-27.89%","lyrEps":-0.027765,"volumeRatio":0.852367,"shares":180786237,"dividePrice":0,"high":2.45,"amplitude":0.082969,"preClose":2.29,"low":2.26,"week52Low":0.92,"pbRate":"27.66","psRate":"73.30","week52High":4.9,"institutionHeld":0,"latestPrice":2.45,"committee":-0.647679,"eps":-0.0278,"divideRate":0,"volume":108691,"delay":0,"ttmEps":-0.0278,"open":2.3,"prevYearClose":2.73,"prevWeekClose":2.25,"prevMonthClose":2.23,"prevQuarterClose":2.73,"fiveDayClose":2.25,"twentyDayClose":2.86,"sixtyDayClose":3.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609555609","title":"Racura Oncology Proposes Selective Buyback, Cancellation Of Shares After Administrative Oversight in Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=2609555609","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609555609?lang=en_us&edition=fundamental","pubTime":"2026-02-06 13:11","pubTimestamp":1770354705,"startTime":"0","endTime":"0","summary":"Racura Oncology  is proposing to conduct a selective buyback and cancellation of its shares, subject to shareholder approval at its annual general meeting, after an aggregate of 179,242 additional shares were issued to its Chief Executive Officer Daniel Tillett and former CEO Phillip Lynch, and recorded on the Company's share register, rather than the intended number of 761,828 shares, due to an administrative oversight, according to a Friday Australian bourse filing.It issued 941,090 ordinary shares on Nov. 21, 2025, on the cashless exercise of 4 million unlisted options with an exercise price of AU$2.65 per share expiring Nov. 29, 2025, issued to Tillett and Lynch.The Options were issued to Tillett and Lynch under the company's employee securities incentive plan approved by shareholders at the 2018 Annual General Meeting and were exercised into shares using the cashless exercise facility under that plan.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2607008776","title":"Racura Oncology Says Potential of Proprietary Formulation to be Evaluated Early This Year; Shares Fall 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607008776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607008776?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:36","pubTimestamp":1769657790,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the potential of its proprietary formulation RC220 to prevent or slow resistance to osimertinib treatment in mutant epidermal growth factor receptor  lung cancer will be explored in the clinic early this year, according to a Thursday filing with the Australian bourse.Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined EGFR mutations, the company said in an earlier filing.In-patient effect of the company's lead asset and anti-cancer agent RCDS1  on master cancer growth regulator MYC will be evaluated later in the year, the filing said.Shares of the company fell past 7% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2603042939","title":"Atomic Eagle And 2 More ASX Penny Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2603042939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603042939?lang=en_us&edition=fundamental","pubTime":"2026-01-16 03:02","pubTimestamp":1768503773,"startTime":"0","endTime":"0","summary":"As the Australian market experiences a potential commodities supercycle, driven by surges in metals like gold and silver, investor interest in materials is on the rise. Amid this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at accessible price points. Despite their vintage name, these stocks can still provide surprising value when they are backed by strong financial health and solid fundamentals.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2052001-choice2-main-header/1585186680440","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052001-choice2-main-header/1585186680440"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/energy/asx-aeu/atomic-eagle-shares/news/atomic-eagle-and-2-more-asx-penny-stocks-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/energy/asx-aeu/atomic-eagle-shares/news/atomic-eagle-and-2-more-asx-penny-stocks-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7128","BK7506","AEU.AU","WAF.AU","IGL.AU","PPS.AU","BK7143","BK7132","BK7045","BK7083","BK7067","VRS.AU","BK4211","BK7061","BK7503","MTO.AU","BK7104","BK7016","MXI.AU","VFY.AU","BK7055","BK7048","EGBN","BK7077","DSK.AU","RAC.AU","PPL.AU","EDU.AU","SSM.AU","BK7508","BK7050"],"gpt_icon":0},{"id":"2603755655","title":"Racura Partners With US-University to Study Lead Asset in Osimertinib-Resistant Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603755655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603755655?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:54","pubTimestamp":1768344883,"startTime":"0","endTime":"0","summary":"Racura Oncology  partnered with Emory University to study RCDS1 in osimertinib-resistant, epidermal growth factor receptor mutated  non-small cell lung cancer , according to a Wednesday filing with the Australian bourse.Osimertinib is the current standard of care treatment for NSCLC, the filing said.Under the deal, the company gets access to Emory's osimertinib-resistant cell and mouse NSCLC models and expertise, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAC.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":0.017447}]}}